Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study
Introduction Type 2 diabetes patients complicated by chronic kidney disease (CKD) require restricted use and dose adjustment of orally administered hypoglycemic agents because of renal dysfunction, and treatment is likely to be difficult. Linagliptin and teneligliptin are dipeptidyl-peptidase (DPP)-...
Gespeichert in:
| Veröffentlicht in: | Diabetology International 2016-12, Vol.7 (4), p.368-374 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 374 |
|---|---|
| container_issue | 4 |
| container_start_page | 368 |
| container_title | Diabetology International |
| container_volume | 7 |
| creator | Tanaka, Kenichi Okada, Yosuke Mori, Hiroko Inada, Yoshifumi Suzuka, Kanako Uriu, Kohei Tanaka, Yoshiya |
| description | Introduction
Type 2 diabetes patients complicated by chronic kidney disease (CKD) require restricted use and dose adjustment of orally administered hypoglycemic agents because of renal dysfunction, and treatment is likely to be difficult. Linagliptin and teneligliptin are dipeptidyl-peptidase (DPP)-4 inhibitors that do not require dose adjustment even in type 2 diabetes patients complicated by CKD. The aim of this pilot study was to determine the efficacy of these agents for glycemic control using continuous glucose monitoring (CGM).
Materials and methods
A randomized crossover study was conducted in 13 type 2 diabetes patients with CKD who maintained glycosylated hemoglobin (HbA
1c
) levels at |
| doi_str_mv | 10.1007/s13340-016-0258-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6224979</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A711675243</galeid><sourcerecordid>A711675243</sourcerecordid><originalsourceid>FETCH-LOGICAL-c595t-bf6b880fd40b7dfafa7a851efc0108fec5d693b4106efc2f76b847be3ef346393</originalsourceid><addsrcrecordid>eNp1Ul1v1iAYbYzGLXM_wBtD4nUn0C-qicmybGqyxBu9JpQ-9GW2UIFq-rf8hT5dtzfzQm4gh3MOBzhZ9prRC0Zp8y6yoihpTlmdU16JfH2WnXLW0pzVon5-XDfiJDuP8Y7iKFtGm_pldlLQmhZciNPsz7UxViu9Em_IaJ0aRjsn64hyPUngYLSPiPGBDOOqYbKaaO9S8CNBPK0zEE56qzpIuDWrZMGlSH7bdCD6ELxD9IftHazIiqAivCcqRohxQiLp1ns76xa_RDxi0T4CmVCWfLBu-EAUme3oE4lp6ddX2QujxgjnD_NZ9v3m-tvV5_z266cvV5e3ua7aKuWdqTshqOlL2jW9UUY1SlQMjKaMCgO66uu26EpGa8S4aZBeNh0UYIqyLtriLPu4-85LN0GvMWpQo5yDnVRYpVdW_rvj7EEO_pesOS_bZjN4-2AQ_M8FYpJ3fgkOM0uGyQQvecORdbGzBjWCtM54NMMfUf320N6BsYhfNgz_suJlgQK2C3TwMQYwx0iMyq0acq-GxGrIrRpyRc2bp3c5Kh6LgAS-E-K8PTmEJ1n_6_oXAXzK1w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1880824272</pqid></control><display><type>article</type><title>Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerNature Journals</source><source>PubMed Central</source><creator>Tanaka, Kenichi ; Okada, Yosuke ; Mori, Hiroko ; Inada, Yoshifumi ; Suzuka, Kanako ; Uriu, Kohei ; Tanaka, Yoshiya</creator><creatorcontrib>Tanaka, Kenichi ; Okada, Yosuke ; Mori, Hiroko ; Inada, Yoshifumi ; Suzuka, Kanako ; Uriu, Kohei ; Tanaka, Yoshiya</creatorcontrib><description>Introduction
Type 2 diabetes patients complicated by chronic kidney disease (CKD) require restricted use and dose adjustment of orally administered hypoglycemic agents because of renal dysfunction, and treatment is likely to be difficult. Linagliptin and teneligliptin are dipeptidyl-peptidase (DPP)-4 inhibitors that do not require dose adjustment even in type 2 diabetes patients complicated by CKD. The aim of this pilot study was to determine the efficacy of these agents for glycemic control using continuous glucose monitoring (CGM).
Materials and methods
A randomized crossover study was conducted in 13 type 2 diabetes patients with CKD who maintained glycosylated hemoglobin (HbA
1c
) levels at <9 % by diet and exercise and had estimated glomerular filtration rates (eGFRs) <60 ml/min 1.73 m
2
. They were treated with teneligliptin at 20 mg/day or linagliptin at 5 mg/day for 6 days then switched to the other agent for another 6 days. CGM was performed before and during treatment. The primary outcome was changes in mean amplitude of glucose excursions (MAGE).
Results
Mean MAGE was 83.8 ± 34.0 and 82.6 ± 32.6 [±standard deviation (SD)] during treatment with linagliptin and teneligliptin, respectively, with no significant difference between agents. The two agents showed comparable beneficial effects on 24-h mean sensor glucose levels and area under the curve for sensor glucose levels ≥180 mg/dl (AUC ≥180), and their use was associated with comparable incidence of hypoglycemia.
Conclusions
Linagliptin and teneligliptin have comparable effects on MAGE in type 2 diabetes patients with CKD and are potentially useful and safe for treatment of such patients.</description><identifier>ISSN: 2190-1678</identifier><identifier>EISSN: 2190-1686</identifier><identifier>DOI: 10.1007/s13340-016-0258-y</identifier><identifier>PMID: 30603288</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Blood sugar monitoring ; Care and treatment ; Dextrose ; Diabetes ; Diabetes mellitus ; Diabetes therapy ; Diabetics ; Endocrinology ; Glucose ; Glucose monitoring ; Glycosylated hemoglobin ; Hemoglobin ; Hypoglycemia ; Hypoglycemic agents ; Kidney diseases ; Kidney transplantation ; Linagliptin ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Oral administration ; Original ; Original Article ; Patient monitoring equipment ; Peptidase ; Renal function ; Sensors ; Type 2 diabetes</subject><ispartof>Diabetology International, 2016-12, Vol.7 (4), p.368-374</ispartof><rights>The Japan Diabetes Society 2016</rights><rights>COPYRIGHT 2016 Springer</rights><rights>Copyright Springer Science & Business Media 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c595t-bf6b880fd40b7dfafa7a851efc0108fec5d693b4106efc2f76b847be3ef346393</citedby><cites>FETCH-LOGICAL-c595t-bf6b880fd40b7dfafa7a851efc0108fec5d693b4106efc2f76b847be3ef346393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224979/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224979/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,41493,42562,51324,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30603288$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanaka, Kenichi</creatorcontrib><creatorcontrib>Okada, Yosuke</creatorcontrib><creatorcontrib>Mori, Hiroko</creatorcontrib><creatorcontrib>Inada, Yoshifumi</creatorcontrib><creatorcontrib>Suzuka, Kanako</creatorcontrib><creatorcontrib>Uriu, Kohei</creatorcontrib><creatorcontrib>Tanaka, Yoshiya</creatorcontrib><title>Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study</title><title>Diabetology International</title><addtitle>Diabetol Int</addtitle><addtitle>Diabetol Int</addtitle><description>Introduction
Type 2 diabetes patients complicated by chronic kidney disease (CKD) require restricted use and dose adjustment of orally administered hypoglycemic agents because of renal dysfunction, and treatment is likely to be difficult. Linagliptin and teneligliptin are dipeptidyl-peptidase (DPP)-4 inhibitors that do not require dose adjustment even in type 2 diabetes patients complicated by CKD. The aim of this pilot study was to determine the efficacy of these agents for glycemic control using continuous glucose monitoring (CGM).
Materials and methods
A randomized crossover study was conducted in 13 type 2 diabetes patients with CKD who maintained glycosylated hemoglobin (HbA
1c
) levels at <9 % by diet and exercise and had estimated glomerular filtration rates (eGFRs) <60 ml/min 1.73 m
2
. They were treated with teneligliptin at 20 mg/day or linagliptin at 5 mg/day for 6 days then switched to the other agent for another 6 days. CGM was performed before and during treatment. The primary outcome was changes in mean amplitude of glucose excursions (MAGE).
Results
Mean MAGE was 83.8 ± 34.0 and 82.6 ± 32.6 [±standard deviation (SD)] during treatment with linagliptin and teneligliptin, respectively, with no significant difference between agents. The two agents showed comparable beneficial effects on 24-h mean sensor glucose levels and area under the curve for sensor glucose levels ≥180 mg/dl (AUC ≥180), and their use was associated with comparable incidence of hypoglycemia.
Conclusions
Linagliptin and teneligliptin have comparable effects on MAGE in type 2 diabetes patients with CKD and are potentially useful and safe for treatment of such patients.</description><subject>Blood sugar monitoring</subject><subject>Care and treatment</subject><subject>Dextrose</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes therapy</subject><subject>Diabetics</subject><subject>Endocrinology</subject><subject>Glucose</subject><subject>Glucose monitoring</subject><subject>Glycosylated hemoglobin</subject><subject>Hemoglobin</subject><subject>Hypoglycemia</subject><subject>Hypoglycemic agents</subject><subject>Kidney diseases</subject><subject>Kidney transplantation</subject><subject>Linagliptin</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Oral administration</subject><subject>Original</subject><subject>Original Article</subject><subject>Patient monitoring equipment</subject><subject>Peptidase</subject><subject>Renal function</subject><subject>Sensors</subject><subject>Type 2 diabetes</subject><issn>2190-1678</issn><issn>2190-1686</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1Ul1v1iAYbYzGLXM_wBtD4nUn0C-qicmybGqyxBu9JpQ-9GW2UIFq-rf8hT5dtzfzQm4gh3MOBzhZ9prRC0Zp8y6yoihpTlmdU16JfH2WnXLW0pzVon5-XDfiJDuP8Y7iKFtGm_pldlLQmhZciNPsz7UxViu9Em_IaJ0aRjsn64hyPUngYLSPiPGBDOOqYbKaaO9S8CNBPK0zEE56qzpIuDWrZMGlSH7bdCD6ELxD9IftHazIiqAivCcqRohxQiLp1ns76xa_RDxi0T4CmVCWfLBu-EAUme3oE4lp6ddX2QujxgjnD_NZ9v3m-tvV5_z266cvV5e3ua7aKuWdqTshqOlL2jW9UUY1SlQMjKaMCgO66uu26EpGa8S4aZBeNh0UYIqyLtriLPu4-85LN0GvMWpQo5yDnVRYpVdW_rvj7EEO_pesOS_bZjN4-2AQ_M8FYpJ3fgkOM0uGyQQvecORdbGzBjWCtM54NMMfUf320N6BsYhfNgz_suJlgQK2C3TwMQYwx0iMyq0acq-GxGrIrRpyRc2bp3c5Kh6LgAS-E-K8PTmEJ1n_6_oXAXzK1w</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Tanaka, Kenichi</creator><creator>Okada, Yosuke</creator><creator>Mori, Hiroko</creator><creator>Inada, Yoshifumi</creator><creator>Suzuka, Kanako</creator><creator>Uriu, Kohei</creator><creator>Tanaka, Yoshiya</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>K9.</scope><scope>5PM</scope></search><sort><creationdate>20161201</creationdate><title>Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study</title><author>Tanaka, Kenichi ; Okada, Yosuke ; Mori, Hiroko ; Inada, Yoshifumi ; Suzuka, Kanako ; Uriu, Kohei ; Tanaka, Yoshiya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c595t-bf6b880fd40b7dfafa7a851efc0108fec5d693b4106efc2f76b847be3ef346393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Blood sugar monitoring</topic><topic>Care and treatment</topic><topic>Dextrose</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes therapy</topic><topic>Diabetics</topic><topic>Endocrinology</topic><topic>Glucose</topic><topic>Glucose monitoring</topic><topic>Glycosylated hemoglobin</topic><topic>Hemoglobin</topic><topic>Hypoglycemia</topic><topic>Hypoglycemic agents</topic><topic>Kidney diseases</topic><topic>Kidney transplantation</topic><topic>Linagliptin</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Oral administration</topic><topic>Original</topic><topic>Original Article</topic><topic>Patient monitoring equipment</topic><topic>Peptidase</topic><topic>Renal function</topic><topic>Sensors</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Kenichi</creatorcontrib><creatorcontrib>Okada, Yosuke</creatorcontrib><creatorcontrib>Mori, Hiroko</creatorcontrib><creatorcontrib>Inada, Yoshifumi</creatorcontrib><creatorcontrib>Suzuka, Kanako</creatorcontrib><creatorcontrib>Uriu, Kohei</creatorcontrib><creatorcontrib>Tanaka, Yoshiya</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetology International</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Kenichi</au><au>Okada, Yosuke</au><au>Mori, Hiroko</au><au>Inada, Yoshifumi</au><au>Suzuka, Kanako</au><au>Uriu, Kohei</au><au>Tanaka, Yoshiya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study</atitle><jtitle>Diabetology International</jtitle><stitle>Diabetol Int</stitle><addtitle>Diabetol Int</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>7</volume><issue>4</issue><spage>368</spage><epage>374</epage><pages>368-374</pages><issn>2190-1678</issn><eissn>2190-1686</eissn><abstract>Introduction
Type 2 diabetes patients complicated by chronic kidney disease (CKD) require restricted use and dose adjustment of orally administered hypoglycemic agents because of renal dysfunction, and treatment is likely to be difficult. Linagliptin and teneligliptin are dipeptidyl-peptidase (DPP)-4 inhibitors that do not require dose adjustment even in type 2 diabetes patients complicated by CKD. The aim of this pilot study was to determine the efficacy of these agents for glycemic control using continuous glucose monitoring (CGM).
Materials and methods
A randomized crossover study was conducted in 13 type 2 diabetes patients with CKD who maintained glycosylated hemoglobin (HbA
1c
) levels at <9 % by diet and exercise and had estimated glomerular filtration rates (eGFRs) <60 ml/min 1.73 m
2
. They were treated with teneligliptin at 20 mg/day or linagliptin at 5 mg/day for 6 days then switched to the other agent for another 6 days. CGM was performed before and during treatment. The primary outcome was changes in mean amplitude of glucose excursions (MAGE).
Results
Mean MAGE was 83.8 ± 34.0 and 82.6 ± 32.6 [±standard deviation (SD)] during treatment with linagliptin and teneligliptin, respectively, with no significant difference between agents. The two agents showed comparable beneficial effects on 24-h mean sensor glucose levels and area under the curve for sensor glucose levels ≥180 mg/dl (AUC ≥180), and their use was associated with comparable incidence of hypoglycemia.
Conclusions
Linagliptin and teneligliptin have comparable effects on MAGE in type 2 diabetes patients with CKD and are potentially useful and safe for treatment of such patients.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>30603288</pmid><doi>10.1007/s13340-016-0258-y</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2190-1678 |
| ispartof | Diabetology International, 2016-12, Vol.7 (4), p.368-374 |
| issn | 2190-1678 2190-1686 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6224979 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerNature Journals; PubMed Central |
| subjects | Blood sugar monitoring Care and treatment Dextrose Diabetes Diabetes mellitus Diabetes therapy Diabetics Endocrinology Glucose Glucose monitoring Glycosylated hemoglobin Hemoglobin Hypoglycemia Hypoglycemic agents Kidney diseases Kidney transplantation Linagliptin Medicine Medicine & Public Health Metabolic Diseases Oral administration Original Original Article Patient monitoring equipment Peptidase Renal function Sensors Type 2 diabetes |
| title | Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T23%3A42%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20linagliptin%20and%20teneligliptin%20for%20glycemic%20control%20in%20type%202%20diabetic%20patients%20with%20chronic%20kidney%20disease:%20assessment%20by%20continuous%20glucose%20monitoring;%20a%20pilot%20study&rft.jtitle=Diabetology%20International&rft.au=Tanaka,%20Kenichi&rft.date=2016-12-01&rft.volume=7&rft.issue=4&rft.spage=368&rft.epage=374&rft.pages=368-374&rft.issn=2190-1678&rft.eissn=2190-1686&rft_id=info:doi/10.1007/s13340-016-0258-y&rft_dat=%3Cgale_pubme%3EA711675243%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1880824272&rft_id=info:pmid/30603288&rft_galeid=A711675243&rfr_iscdi=true |